Last reviewed · How we verify
Tc 99m tilmanocept — Competitive Intelligence Brief
marketed
Small molecule
Live · refreshed every 30 min
Target snapshot
Tc 99m tilmanocept (Tc 99m tilmanocept) — Navidea Biopharmaceuticals.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Tc 99m tilmanocept TARGET | Tc 99m tilmanocept | Navidea Biopharmaceuticals | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Tc 99m tilmanocept CI watch — RSS
- Tc 99m tilmanocept CI watch — Atom
- Tc 99m tilmanocept CI watch — JSON
- Tc 99m tilmanocept alone — RSS
Cite this brief
Drug Landscape (2026). Tc 99m tilmanocept — Competitive Intelligence Brief. https://druglandscape.com/ci/tc-99m-tilmanocept. Accessed 2026-05-17.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab